BOUNDLESS BIO, INC.

Analyst Reco. Boundless Bio, Inc.

Equities

BOLD

US10170A1007

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-15 pm EDT			5-day change	1st Jan Change
9.53 ^USD	+2.69%		-3.74%	0.00%

Apr. 22	Guggenheim Starts Coverage on Boundless Bio With Buy Rating, $24 Price Target	MT
Apr. 22	Piper Sandler Starts Audentes Therapeutics With Overweight Rating, $20 Price Target	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Guggenheim Starts Coverage on Boundless Bio With Buy Rating, $24 Price Target	Apr. 22	MT
Piper Sandler Starts Audentes Therapeutics With Overweight Rating, $20 Price Target	Apr. 22	MT
Boundless Bio Insider Bought Shares Worth $3,200,000, According to a Recent SEC Filing	Apr. 04	MT
Boundless Bio Insider Bought Shares Worth $3,200,000, According to a Recent SEC Filing	Apr. 04	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.

BENEFIT NOW